When was Symetis founded?

Symetis was founded in 2001 and raised its 1st funding round 3 years after it was founded.

Where is Symetis located?

Symetis is headquartered in Ecublens, Switzerland.

Who is the current CEO of Symetis?

Jacques R. Essinger of Symetis.

Is Symetis a funded company?

Symetis is a funded company, having raised a total of $56.7M across 3 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Oct 14, 2004.

When was the latest funding round of Symetis?

Symetis' latest funding was a $***** Series C round on Oct 07, 2010, with participation from 8 investors. Its primary sector is Cardiac and Vascular Disorders. In Switzerland, the Cardiac and Vascular Disorders sector has seen $33.3M in funding in 2026 to date.

Where does Symetis rank among its competitors?

Symetis ranks 19th amongst 113 active competitors, of which 51 are funded. It stands 7th in terms of total funding among its competitors. The most recent competitor to raise funding was CroiValve, which secured $20M in Jun, 2026.

Symetis - 2026 Company Profile, Team, Funding & Competitors

Q: Is Symetis an acquired company?

Symetis got acquired by Boston Scientific on Mar 30, 2017.

Q: Who are the top competitors of Symetis?

Symetis' top competitors include Shockwave Medical, Cardiac Dimensions and MicroPort CardioFlow Medtech Corporation. Among them, CroiValve secured the most recent funding round in June, 2026.

Company Details

Symetis develops minimally invasive heart valve replacement therapies for patients suffering from heart valve diseases. Its proprietary Acurate TA and Acurate neo along with their respective delivery systems are marketed in Europe and other markets. Has manufacturing facilities in Brazil and Switzerland. Puts its planned IPO on hold in late 2015.

Key Metrics

Founded Year

2001

Location

Ecublens, Switzerland

Stage

Acquired

Total Funding

$56.7M in 3 rounds

Latest Funding Round

Series C, Oct 07, 2010, $*****

Investors

Wellington Partners Venture Capital & 12 more

Ranked

19^th among 113 active competitors

Investment & Acquisitions

Middle Peak Medical

Similar Companies

Shockwave Medical & 146 more

Exit Details

Acquired by Boston Scientific (Mar 30, 2017)

View Symetis' full profile

Symetis got acquired by Boston Scientific on Mar 30, 2017 at an acquisition amount of $*****.

Click here to take a look at Symetis's acquisition in detail

Symetis has raised a total funding of $56.7M over 3 rounds. Its first funding round was on Oct 14, 2004. Its latest funding round was a Series C round on Oct 07, 2010 for $*****. 8 investors participated in its latest round. Symetis has 13 institutional investors.

Here is the list of recent funding rounds of Symetis:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Oct 07, 2010	2227803	Series C	4590854	9217783	2281766	3768043
Jul 02, 2009	1097445	Series B	8150544	6786047	2605760	Truffle Capital & 4 more
Oct 14, 2004	7854691	Series A	8435653	5572383	Truffle Capital & 1 more	Novartis Venture Fund & 2 more

Access funding benchmarks and valuations. Sign up today!

View details of Symetis's funding rounds and investors

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Symetis include Shockwave Medical, Cardiac Dimensions and MicroPort CardioFlow Medtech Corporation. Here is the list of Top 10 competitors of Symetis, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Shockwave Medical 2009, Santa Clara (United States), Acquired	Developer of cardiovascular balloon dilation catheters	$148M	Sofinnova Partners, Venrock & 9 others	65/100
2nd	Cardiac Dimensions 2001, Kirkland (United States), Series E	Developer of invasive cardiac implants for heart failure	$261M	Life Sciences Partners, Lumira Ventures & 20 others	63/100
3rd	MicroPort CardioFlow Medtech Corporation 2015, Pudong (China), Public	Developer of smart medical devices for patients with heart valve diseases	$132M	Lake Bleu Capital, CICC & 10 others	63/100
4th	Peijia Medical Technologies 2012, Suzhou (China), Public	Developer of medical devices for the treatment of cardiac and cerebrovascular diseases	$110M	Lilly Asia Ventures, SDIC Innovation & 9 others	63/100
5th	JenaValve Technology 2006, Irvine (United States), Acquired	Provider of pericardial transcatheter aortic valve replacement and delivery system	$364M	Sunstone, Valiance Asset Management & 19 others	62/100
6th	Venus MedTech 2009, Hangzhou (China), Public	Transcatheter aortic valves	$37M	DCP, HongShan & 6 others	62/100
7th	CroiValve 2016, Dublin (Ireland), Series B	Developer of a percutaneous device for treating tricuspid regurgitation	$52.1M	Irrus Investments, Halo Business Angel Network ... & 21 others	58/100
8th	TRiCares 2013, Aschheim (Germany), Series D	Developer of a minimally invasive tricuspid valve replacement system. This system is designed to treat tricuspid regurgitation, a serious heart condition, without the need for open-heart surgery. The company focuses on developing a safe and effective solution to address the limitations of existing treatment approaches. It is developing a catheter-based system for tricuspid valve replacement. The company's efforts include clinical trials and securing funding to support further development and clinical milestones.	$103M	415 CAPITAL, Lifeblood Capital & 10 others	58/100
9th	Foldax 2006, Salt Lake City (United States), Series D	Developer of bio-polymeric heart valves to treat aortic, mitral, and tricuspid valve diseases	$43.7M	MemorialCare Innovation Fund, BioStar Capital ... & 3 others	56/100
10th	HighLife Medical 2010, Paris (France), Series B	Developer of trans-catheter mitral valve replacement system	$50.8M	USVP, Sofinnova Partners & 7 others	56/100
19th	Symetis 2001, Ecublens (Switzerland), Acquired	Heart valve replacement devices	$56.7M	Kreos Capital, Stage Capital & 11 others	49/100